Back

Effect of acoramidis on improvement or maintenance of heart failure-related health status as assessed by Kansas City Cardiomyopathy Questionnaire Overall Summary score (KCCQ-OS) in ATTRibute-CM

9 May 2026 (15:36 - 16:30)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease (2) Clinical HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Charles Sherrod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

8 More presentations in this session

Presentation thumbnail
Weak grip, slow rise - associations with cardiac enzymes and NYHA functional class: handgrip strength and chair rise test performance as potential prognostic markers in cardiac ATTR and AL amyloidosis
Ms C. Dolderer (Wuerzburg, DE)
Abstract Slides
Presentation thumbnail
Advanced echocardiographic phenotyping reveals distinct functional patterns in cardiomyopathies with increased LV mass
Doctor F. Sahiti (Wurzburg, DE)
Abstract Slides
Presentation thumbnail
The heart after transplant: long-term cardiovascular outcomes in hereditary ATTRv Amyloidosis
Doctor J. AGOSTINHO (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Cardiac amyloidosis in older patients: can we predict hereditary vs wild-type subtype?
Doctor B. Andrade (Santarem, PT)
Abstract Slides
Presentation thumbnail
Takotsubo syndrome in real-world practice: a tertiary centre case series
Doctor J. Fernandes Pedro (Lisbon, PT)
Abstract Slides

Access the full session

Session thumbnail
ePosters in myocardial disease (2)

The Event

Event poster

Heart Failure 2026

9 May 2026 15:36 CET
You may be interested in
thumbnail
Congress Presentation
Improved health-related quality of life in acoramidis-treated patients with ATTR-CM, demonstrated by improvements in KCCQ scores
13 May 2024
thumbnail
Congress Presentation
Improved survival with around 5 years of continuous tafamidis treatment among patients with NYHA class III transthyretin amyloid cardiomyopathy
21 May 2022
thumbnail
Congress Presentation
Psychometric analysis of the kansas city cardiomiopathy questionnaire-23 in a european population
15 June 2024
thumbnail
Congress Presentation
functional capacity assessment of cardiac amyloidosis patients before treatment and rehabilitation
13 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources